


**Listing of the claims**

1. (Currently amended) A method of treating or preventing [[a]] atypical depression secondary to pain (DSP) in an individual suffering from DSP or at risk thereof, which comprises the method comprising administering to the individual an effective amount of a dual norepinephrine serotonin reuptake inhibitor (NSRI) or triple reuptake inhibitor (TRI) to alleviate or prevent at least one symptom of [[a]] atypical depression.
2. (Original) The method of claim 1 wherein the selective NSRI has an NE: 5-HT reuptake inhibition ratio of about 1:1 to about 50:1.
3. (Original) The method of claim 1 wherein the selective NSRI has an NE: 5-HT reuptake inhibition ratio of about 1:1 to about 20:1.
4. (Currently amended) The method of claim 1 wherein the selective norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI) is milnacipran:



or stereoisomeric forms, mixtures of stereoisomeric forms, metabolites, derivatives, or pharmaceutically acceptable salts thereof.

5. (Original) The method of claim 4 wherein the milnacipran is administered at a dosage of between 100 and 400 mg/day.

6. (Original) The method of claim 4 wherein the milnacipran is administered at a dosage of between 100 and 250 mg/day.

7. (Original) The method of claim 1 wherein the inhibitor is administered two or more times per day.

8. (Original) The method of claim 1 wherein the NSRI has NMDA receptor antagonist properties.

9. (Original) The method of claim 1 wherein the selective norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI) does not substantially increase the risk of seizures.

10. (Original) The method of claim 1 wherein the selective norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI) comprises at least two of milnacipran, sibutramine, and an aminocyclopropane derivative.

11. (Withdrawn) The method of claim 1 wherein the inhibitor is a triple reuptake inhibitor blocking uptake of serotonin, noradrenaline, and dopamine.

12. (Currently amended) The method of claim 1 wherein the DSP comprises [[a]] atypical depression and either chronic pain or neuropathic pain.

13. (Currently amended) The method of claim 12 wherein the DSP comprises chronic pain selected from the group consisting of lower back pain, [[a]] atypical chest pain, headache, pelvic pain, myofascial face pain, abdominal pain, neck pain and chronic pain caused by a disease or condition.

14. (Currently amended) The method of claim 1 wherein the DSP comprises [[a]]  
atypical depression characterized by mood reactivity and neurovegetative symptoms present for  
more than about two weeks.

15-18. (Canceled)